readthroughSign in
Nov 10, 2026Quarterly update

NextCure reports Q3 2026 results as Avere merger financing grows to $820 million

Stockholders will vote December 9 on the deal after the SEC cleared NextCure's S-4, while cash fell to $8.7 million.

NextCure, Inc. provided a business update and reported third quarter 2026 financial results on November 10, 2026, as it continues toward a shareholder vote on its proposed merger with Avere Therapeutics, Inc., a privately held biotechnology company focused on oral therapies for IL-23-driven inflammatory diseases.1

The Registration Statement on Form S-4 relating to the proposed merger was declared effective by the SEC on November 6, 2026, and the company set November 3, 2026 as the record date and scheduled a special stockholder meeting for December 9, 2026 at 9:00 a.m. Eastern Time.1 Separately, a Delaware Court of Chancery order dated November 2, 2026 confirmed the validity of NextCure's July 2025 reverse stock split and the shares issued under it.1

Financing backing the deal has expanded. Commitments now total approximately $820 million, made up of the previously announced $320 million concurrent private placement plus an additional $500 million private placement, with about $266 million of that to be satisfied by converting and canceling Avere's outstanding convertible notes.1 The company said the funding is expected to support development of Avere's lead program, AVR-001, along with other corporate purposes and the combined company's future operations.1 If completed, the combined company is expected to operate as Avere and trade on Nasdaq under the ticker "AVRX."1 Existing NextCure stockholders are expected to keep an ownership stake and receive contingent value rights tied to specified legacy NextCure assets.1

On the legacy pipeline, NextCure and LigaChem Biosciences, Inc. signed a Transition and Continuation Agreement in August 2026 under which LigaChem became sole developer of the LNCB74 program and took over costs from July 1, 2026, with the IND and related regulatory responsibilities transferred to LigaChem on October 6, 2026.1 NextCure remains eligible for future milestone payments and royalties tied to LNCB74.1 Treatment and transition activities for patients in the SIM0505 study concluded by August 31, 2026, and the company is still looking at ways to partner or license that program.1

On finances, cash, cash equivalents and marketable securities stood at $8.7 million as of September 30, 2026, down from $41.8 million at the end of 2025.1 Net loss for the quarter was $6.8 million, compared with $8.6 million a year earlier.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.